Pfizer and Crucell in research license agreement
Dutch biotechnology company Crucell, developer of the proprietary PER.C6 production cell line technology, has signed a research license agreement with Pfizer Animal Health that will allow Pfizer to use the technology to develop a non-disclosed veterinary vaccine. Financial details of the deal were also not disclosed, but Crucell said that Pfizer had an option to commercialize the license. Spokespersons from both companies declined to comment further. The technology is used for the production of human and animal vaccines, antibodies, and gene therapies, among others; in December 2002, Crucell formed an alliance with DSM Biologics to expand manufacturing to therapeutic proteins and monoclonal antibodies. Crucell says that many of its pipeline products are based on its technology - these include vaccines for Ebola, West Nile virus, influenza, malaria, tuberculosis, and rabies.